Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Washington D.C., District of Columbia

Phase 1 cancer trials in Washington D.C., DC

36 Phase 1 cancer studies are recruiting participants at sites in Washington D.C. as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Washington D.C. at a glance

Breast cancer studies recruiting in Washington D.C.

Basic details from each study's public record (the 30 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    Georgetown University Medical Center
    Registry record
    NCT06270706 · updated
  2. A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

    • Phase 1
    • Ages 18 to 55
    • Female participants
    Sponsor
    TerSera Therapeutics LLC
    Study site
    MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center
    Registry record
    NCT07310420 · updated
  3. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ORIC Pharmaceuticals
    Study site
    Georgetown University
    Registry record
    NCT05315700 · updated
  4. A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    Georgetown University Medical Center
    Registry record
    NCT07029399 · updated
  5. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Georgetown University Medical Center
    Registry record
    NCT05983432 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Lung cancer studies recruiting in Washington D.C.

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT05786924 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT06287775 · updated
  3. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Johns Hopkins Sibley Memorial Hospital
    Registry record
    NCT07277413 · updated
  4. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Georgetown University - Lombardi Comprehensive Cancer Center
    Registry record
    NCT07111520 · updated
  5. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Georgetown University
    Registry record
    NCT04886804 · updated
  6. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    • Phase 1/2
    • Ages 18 to 80
    • All sexes
    Sponsor
    VM Oncology, LLC
    Study site
    The George Washington University Cancer Center (site 212)
    Registry record
    NCT03556228 · updated
  7. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BlossomHill Therapeutics
    Study site
    Georgetown University Medical Center
    Registry record
    NCT06706076 · updated
  8. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Synthekine
    Study site
    Georgetown University
    Registry record
    NCT05098132 · updated
  9. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tango Therapeutics, Inc.
    Study site
    Georgetown University Medical Center
    Registry record
    NCT06922591 · updated
  10. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tango Therapeutics, Inc.
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06810544 · updated
  11. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Georgetown University Medical Center
    Registry record
    NCT06162221 · updated
  12. AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Avenzo Therapeutics, Inc.
    Study site
    Avenzo Therapeutics Recruiting Site
    Registry record
    NCT07038343 · updated
  13. A Study of PHN-012 in Patients With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pheon Therapeutics
    Study site
    PHN-012-001 Site
    Registry record
    NCT07127874 · updated
  14. A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    MediLink Therapeutics (Suzhou) Co., Ltd.
    Registry record
    NCT07407933 · updated
  15. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sutro Biopharma, Inc.
    Study site
    Georgetown University Medical Center
    Registry record
    NCT07227168 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Prostate cancer studies recruiting in Washington D.C.

  1. A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
    Registry record
    NCT06863272 · updated
  2. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    Johns Hopkins University, Sibley Memorial Hospital
    Registry record
    NCT05919264 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Melanoma studies recruiting in Washington D.C.

  1. Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)

    • Phase 1
    • Ages 3 to 25
    • All sexes
    Sponsor
    Children's National Research Institute
    Study site
    Children's National Hospital
    Registry record
    NCT07796061 · updated
  2. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT05896839 · updated
  3. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    • Phase 1/2
    • From 12 months, up to 30 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Children's National Medical Center
    Registry record
    NCT04851119 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Lymphoma studies recruiting in Washington D.C.

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Children's National Medical Center
    Registry record
    NCT04726241 · updated
  2. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study site
    Georgetown University Medical Center
    Registry record
    NCT05384626 · updated
  3. A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

    • Phase 1
    • Ages 4 and older
    • All sexes
    Sponsor
    University of Florida
    Study site
    Children's National Hospital
    Registry record
    NCT04573140 · updated
  4. CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

    • Phase 1/2
    • From 12 months, up to 21 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Children's National Medical Center
    Registry record
    NCT04870944 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Washington D.C.

  1. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    The Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins)
    Registry record
    NCT04657068 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Ask about studies near Washington D.C.

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call